Stem Cell Research & Therapy · 2020 · 81 citations · 50 references
Life SciencesCell BiologyNeuroscienceCellular NeuroscienceRegenerative MedicineStem Cell BiologyMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyOptic NerveRetinal Ganglion Cell FunctionRetinal Ganglion CellsRetinal TraumaExtracellular VesiclesGanglion Cell LossHuman Embryonic Stem CellsOptic Nerve InjuryOptic Nerve TraumaRetinal Ganglion Cell BiologyRetinal Ganglion Cell NeuroprotectionRetinal Neuroprotection
BACKGROUND: Retinal and/or optic nerve injury is one of the leading causes of blindness due to retinal ganglion cell (RGC) degeneration. There have been extensive efforts to suppress this neurodegeneration. Various somatic tissue-derived mesenchymal stem cells (MSCs) demonstrated significant neuroprotective and axogenic effects on RGCs. An alternative source of MSCs could be human embryonic stem cells (ES-MSCs), which proliferate faster, express lower levels of inflammatory cytokines, and are capable of immune modulation. It has been demonstrated that MSCs secrete factors or extracellular vesicles that may heal the injury. However, possible therapeutic effects and underlying mechanism of human ES-MSC extracellular vesicles (EVs) on optic nerve injury have not been assessed. METHODS: EVs were isolated from human ES-MSCs. Then, ES-MSC EV was applied to an optic nerve crush (ONC) mouse model. Immunohistofluorescence, retro- and anterograde tracing of RGCs, Western blot, tauopathy in RGCs, and function assessments were performed during 2-month post-treatment to evaluate ONC improvement and underlying mechanism of human ES-MSC EV in in vivo. RESULTS: We found that the ES-MSC EV significantly improved Brn3a+ RGCs survival and retro- and anterograde tracing of RGCs, while preventing retinal nerve fiber layer (RNFL) degenerative thinning compared to the vehicle group. The EVs also significantly promoted GAP43+ axon counts in the optic nerve and improved cognitive visual behavior. Furthermore, cis p-tau, a central mediator of neurodegeneration in the injured RGCs, is detectable after the ONC at the early stages demonstrated tauopathy in RGCs. Notably, after EV treatment cis p-tau was downregulated. CONCLUSIONS: Our findings propose that human ES-MSC EVs, as an off-the-shelf and cell-free product, may have profound clinical implications in treating injured RGCs and degenerative ocular disease. Moreover, the possible mechanisms of human ES-MSC EV are related to the rescue of tauopathy process of RGC degeneration.
50
Cryo-EM structures of tau filaments from Alzheimer’s disease
Anthony W. P. Fitzpatrick, Benjamin Falcon, Shaoda He et al. · Nature · 2017 · 2.1K citations
Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Asami Kondo, Koorosh Shahpasand, Rebekah Mannix et al. · Nature · 2015 · 448 citations · Full text
Near-atomic model of microtubule-tau interactions
Elizabeth H. Kellogg, Nisreen M.A. Hejab, Simon Poepsel et al. · Science · 2018 · 428 citations